Literature DB >> 7669641

Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens.

Y Tokura1, H Yagi, A Ohshima, S Kurokawa, H Wakita, R Yokote, S Shirahama, F Furukawa, M Takigawa.   

Abstract

It has previously been shown that circulating Sézary cells respond in vitro to superantigenic staphylococcal exotoxins in a manner that is restricted by their V beta usage. This study was conducted to examine whether cutaneous colonization with Staphylococcus aureus influences the activity of the skin lesions of Sézary syndrome, and whether S. aureus isolated from patients with Sézary syndrome stimulates circulating Sézary cells in vitro. Two patients with Sézary syndrome, whose skin was colonized with S. aureus, were treated with antibacterial agents, and the relation between the severity of the skin disease and the degree of S. aureus colonization was assessed. In addition, the patients' peripheral blood mononuclear cells were cultured in the presence of mitomycin C-treated S. aureus or superantigenic staphylococcal toxins. The antibacterial treatment improved the skin disease, and eliminated S. aureus in both patients. In one patient, 98% of the peripheral blood mononuclear cells bore V alpha 2V beta 17 of the T-cell receptor, indicative of the presence of an extremely high percentage of circulating Sézary cells. The peripheral blood lymphocytes from this patient responded well in vitro to superantigenic staphylococcal enterotoxin (SE), but not to SEA or toxic shock syndrome toxin-1, or to mitomycin-treated S. aureus isolated from the same patient. Cutaneous colonization by S. aureus influences the disease activity of CTCL, possibly by activation of Sézary cells by bacterial superantigenic exoproteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669641     DOI: 10.1111/j.1365-2133.1995.tb02485.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  23 in total

1.  Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.

Authors:  Anders Woetmann; Paola Lovato; Karsten W Eriksen; Thorbjørn Krejsgaard; Tord Labuda; Qian Zhang; Anne-Merethe Mathiesen; Carsten Geisler; Arne Svejgaard; Mariusz A Wasik; Niels Ødum
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

2.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

3.  Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.

Authors:  Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov
Journal:  J Invest Dermatol       Date:  2017-11-08       Impact factor: 8.551

4.  Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.

Authors:  Lise M Lindahl; Andreas Willerslev-Olsen; Lise M R Gjerdrum; Pia R Nielsen; Edda Blümel; Anne H Rittig; Pamela Celis; Bjorn Herpers; Jürgen C Becker; Birgitte Stausbøl-Grøn; Mariusz A Wasik; Maria Gluud; Simon Fredholm; Terkild B Buus; Claus Johansen; Claudia Nastasi; Lukas Peiffer; Linda Kubat; Michael Bzorek; Jens O Eriksen; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Carsten Geisler; Tomas Mustelin; Erik Langhoff; Michael Givskov; Anders Woetmann; Mogens Kilian; Thomas Litman; Lars Iversen; Niels Odum
Journal:  Blood       Date:  2019-07-22       Impact factor: 22.113

Review 5.  Infectious agents in cutaneous T-cell lymphoma.

Authors:  Ezra D Mirvish; Rebecca G Pomerantz; Larisa J Geskin
Journal:  J Am Acad Dermatol       Date:  2010-08-07       Impact factor: 11.527

6.  Immunological study on CD3 defective cutaneous T cell lymphoma cells from a patient with Sézary syndrome.

Authors:  S Sano; Y Matsui; S Itami; K Yoshikawa
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 7.  Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy.

Authors:  Ivan V Litvinov; Anna Shtreis; Kenneth Kobayashi; Steven Glassman; Matthew Tsang; Anders Woetmann; Denis Sasseville; Niels Ødum; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2016-06-06       Impact factor: 8.110

8.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

9.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

10.  Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.